Microfluidic-derived docosahexaenoic acid liposomes for glioblastoma therapy

last updated: 2024-01-26
ProjectHEALTH UNORTE :: publications list
TitleMicrofluidic-derived docosahexaenoic acid liposomes for glioblastoma therapy
Publication TypePapers in Scientific Journals
Year of Publication2023
AuthorsMendanha D., Gimondi S., Costa B. M., Ferreira H., and Neves N. M.

Glioblastoma (GBM) is the most prevalent malignant primary brain tumor and currently lacks an effective
treatment. In this study, we utilized a microfluidic system to synthesize docosahexaenoic acid (DHA) liposomes for GBM therapy. DHA is an omega-3 (ω3) polyunsaturated fatty acid commonly found in human dietary consumption that has demonstrated potential in mitigating cancer development. The microfluidic device employed allowed for precise fine-tuning of the physicochemical properties of liposomes by adjusting the flow rate ratios, flow rates, and lipid concentrations. Three distinct-sized liposomes, ranging from 80 nm and 130 nm, were successfully internalized by GBM cells, and demonstrated the ability to reduce the viability of these cells. Furthermore, DHA liposomes proved significantly more efficient in triggering apoptotic pathways, through caspase-3-dependent mechanisms, in comparison to free DHA. Thus, the nanomedicine platform established in this study presents new opportunities in the development of liposome formulations incorporating ω3 fatty acids for cancer therapy.

JournalNanomedicine: Nanotechnology, Biology, and Medicine
Date Published2023-08-14
KeywordsDocosahexaenoic acid, Glioblastoma, Liposome, Microfluidics
Peer reviewedyes

Back to top